SCHEMBL27217254

SCHEMBL27217254

Brc1cn[nH]c1-c1cncnc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ DYRK1A Q13627 1/20 0.42
▸ DYRK1B Q9Y463 1/20 0.42
▸ ATM Q13315 1/20 0.33
▸ CYP1A2 P05177 1/20 0.33
▸ METAP2 P50579 1/20 0.33
▸ RPS6KA3 P51812 2/20 0.32
▸ MARK3 P27448 2/20 0.32
▸ AURKA O14965 1/20 0.32
▸ CDK1 P06493 1/20 0.32
▸ LYN P07948 1/20 0.32
▸ PIM1 P11309 1/20 0.32
▸ FGFR1 P11362 1/20 0.32
▸ PRKACA P17612 1/20 0.32
▸ RPS6KB1 P23443 1/20 0.32
▸ CDK2 P24941 1/20 0.32
▸ AKT1 P31749 1/20 0.32
▸ GSK3B P49841 1/20 0.32
▸ PRKCZ Q05513 1/20 0.32
▸ PRKCD Q05655 1/20 0.32
▸ ERBB4 Q15303 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27217094 0.74 RPS6KA3 (0.52) DYRK1ADYRK1BATMCYP1A2METAP2
SCHEMBL31111583 0.67 MAPK14 (0.51) RPS6KA3MARK3AURKACDK1LYN
SCHEMBL2814958 0.63 ATM (0.65) ATMCYP1A2AURKACYP2A6AURKB
SCHEMBL30919457 0.60 TGFBR1 (0.60) CYP1A2METAP2MAPK14
SCHEMBL26453218 0.60 TGFBR1 (0.60) CYP1A2METAP2MAPK14
SCHEMBL31290743 0.60 ATM (0.61) ATMCYP1A2AURKACYP2A6AURKB
SCHEMBL17240178 0.60 DYRK1A (0.34) DYRK1ADYRK1BATMAURKACYP2A6
SCHEMBL13341454 0.59 — —
SCHEMBL1246645 0.59 — —
SCHEMBL13910998 0.58 ATM (0.50) ATMCYP1A2METAP2AURKACYP2A6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4584259-A1 CK1ALPHA AND DUAL CK1ALPHA / GSPT1 DEGRADING COMPOUNDS Innovo Therapeutics, Inc. (US) 2025-07-16 — — EP disclosed
US-20240158370-A1 CK1 alpha AND DUAL CK1 alpha / GSPT1 DEGRADING COMPOUNDS INNOVO THERAPEUTICS, INC. 2024-05-16 — — US disclosed
WO-2024054832-A1 CK1α AND DUAL CK1α / GSPT1 DEGRADING COMPOUNDS INNOVO THERAPEUTICS, INC. (US) 2024-03-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240158370-A1 CK1 alpha AND DUAL CK1 alpha / GSPT1 DEGRADING COMPOUNDS CKS1B, CKS2, MARK1 DYRK1A 559/4885DYRK1B 578/4885ATM 1623/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback